Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Nvidia Share Price Could Be Hit Hard By Iran War - 2Russia Fields New Ulan-2 All-Terrain Tactical Vehicle
- 3Cyber Monday streaming deals 2025: Grab the Disney+ Hulu bundle for only $5 and save over 60%
- 4King Charles shares cancer treatment update, says it's a 'personal blessing'
- 5Which Instax Camera Would it be a good idea for you to Purchase?
- Earthquake in Indonesia kills at least 1 person and sets off small tsunami
- NASA's Apollo 8 moonshot saved 1968. Could Artemis 2 do the same in 2026?
- They died 'doing what they loved': The stories of workers in their 80s who died on the job
- Minute Maid’s frozen juice concentrate is ending after 80 years — and so is a certain kind of kitchen ritual
- Flu season is underway. What are common symptoms to watch for?
- US FDA declines to approve Corcept's drug for rare hormonal disorder
- Turkey’s intel chief lays out country’s vision for Middle East, world
- The Quadrantid meteor shower peaks tonight, but will the full 'Wolf Moon' outshine the show?
- France honors the victims of the Paris attacks' night of terror 10 years on
